Oramed Pharmaceuticals In... (ORMP)
NASDAQ: ORMP
· Real-Time Price · USD
2.08
-0.04 (-1.89%)
At close: Aug 15, 2025, 3:59 PM
2.07
-0.48%
After-hours: Aug 15, 2025, 05:49 PM EDT
Oramed Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 | Feb 28, 2021 |
Revenue | n/a | n/a | 674K | 1.34M | 2.02M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | 674K | 1.34M | 2.02M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M | 2.7M |
Operating Income | -13.06M | -12.87M | -13.52M | -15.77M | -21.63M | -26.93M | -34.55M | -40.6M | -38.92M | -38.14M | -32.84M | -26.46M | -24.22M | -19.83M | -15.99M |
Interest Income | 37.71M | 38.14M | 26.39M | 22.89M | 4.51M | 4.08M | 1.95M | 894K | 1.03M | 1.03M | 681K | 137K | n/a | 121K | 321K |
Pretax Income | 7.16M | 22.38M | 10.23M | 5.09M | -16.94M | -20.81M | -30.57M | -37.66M | -37.03M | -37.06M | -31.62M | -25.52M | -22.99M | -18.8M | -15.46M |
Net Income | 4.46M | 20.86M | 10.46M | 7.12M | -14.76M | -18.79M | -28.13M | -36.75M | -36.1M | -35.7M | -30.38M | -24.56M | -22.24M | -18.38M | -15.46M |
Selling & General & Admin | 6.43M | 7.52M | 8.47M | 8.14M | 9.17M | 10.76M | 11.03M | 15.66M | 14.84M | 13.57M | 11.95M | 7.53M | 5.94M | 4.42M | 4.15M |
Research & Development | 6.63M | 5.34M | 5.72M | 8.97M | 14.48M | 18.87M | 26.23M | 27.64M | 26.77M | 27.27M | 23.59M | 21.63M | 20.99M | 18.11M | 14.54M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 13.06M | 12.87M | 14.2M | 17.11M | 23.65M | 29.63M | 37.26M | 43.3M | 41.61M | 40.84M | 35.54M | 29.16M | 26.93M | 22.53M | 18.69M |
Interest Expense | 17.48M | 2.89M | 2.63M | 2.04M | 826K | 1.04M | 1.39M | 1.93M | 2.1M | 1.07M | 1.21M | 928K | 1.01M | 1.15M | 661K |
Selling & Marketing Expenses | n/a | -663K | -471K | -287K | 131K | 1.26M | 1.45M | 1.85M | 2.02M | 1.55M | 1.18M | 585K | n/a | n/a | n/a |
Cost & Expenses | 13.06M | 12.87M | 14.2M | 17.11M | 23.65M | 29.63M | 37.26M | 43.3M | 41.61M | 40.84M | 35.54M | 29.16M | 26.93M | 22.53M | 18.69M |
Income Tax Expense | 2.77M | 2.01M | 254K | -1.56M | -1.75M | -2.02M | -2.44M | -910K | -925K | -1.36M | -1.24M | -1.22M | -1.27M | -1.07M | -643K |
Shares Outstanding (Basic) | 40.9M | 40.96M | 40.84M | 40.38M | 40.45M | 40.23M | 40.04M | 39M | 39.1M | 38.8M | 38.68M | 36.67M | 29.93M | 29.93M | 27M |
Shares Outstanding (Diluted) | 40.9M | 41.59M | 41.56M | 40.51M | 40.45M | 40.23M | 40.04M | 39M | 39.1M | 38.8M | 38.68M | 36.67M | 29.93M | 29.93M | 27M |
EPS (Basic) | 0.11 | 0.51 | 0.26 | 0.18 | -0.37 | -0.48 | -0.72 | -0.95 | -0.95 | -0.99 | -0.89 | -0.79 | -0.8 | -0.7 | -0.63 |
EPS (Diluted) | 0.11 | 0.51 | 0.26 | 0.18 | -0.37 | -0.48 | -0.72 | -0.95 | -0.95 | -0.99 | -0.89 | -0.79 | -0.8 | -0.7 | -0.63 |
EBITDA | 24.86M | 25.49M | 10.6M | 3.25M | -18.1M | -23.87M | -31.54M | -37.61M | -38.73M | -37.95M | -32.63M | -26.23M | -24.15M | -19.9M | -15.88M |
EBIT | 24.64M | 27.73M | 12.84M | 5.51M | -18.74M | -26.93M | -34.55M | -40.6M | -30.86M | -30.08M | -24.78M | -18.4M | -24.22M | -16.81M | -10.7M |
Depreciation & Amortization | 215K | 217K | 215K | 196K | 3.09M | 3.06M | 3.02M | 2.99M | 53K | 57K | 70K | 87K | 77K | 60K | 35K |